- Home
- MREO vs BEAT Comparison
MREO vs BEAT Comparison
Compare MREO & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | BEAT |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | 16 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 44.8M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | MREO | BEAT |
|---|---|---|
| Price | $0.33 | $1.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $1.50 | ★ $5.63 |
| AVG Volume (30 Days) | ★ 1.4M | 479.6K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $6,000.20 | N/A |
| Revenue Next Year | $34.71 | $315.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.54 |
| 52 Week High | $2.94 | $4.00 |
Technical Indicators
Market Signals| Indicator | MREO | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 41.52 |
| Support Level | $0.32 | $0.91 |
| Resistance Level | $0.42 | $1.35 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 42.31 | 45.56 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.